The main reason for the development of myasthenia gravis is that there is a problem with the neuromuscular junction, which leads to muscle contraction and weakness due to insufficient concentration of acetylcholine. The main reason for the treatment of myasthenia gravis is that it is a cholinesterase inhibitor that prevents the breakdown of acetylcholine in the synaptic gap, thus indirectly increasing the concentration of acetylcholine and improving the muscle transmission of the neuromuscular head to improve the muscle weakness of myasthenia gravis. In addition to the use of bromipyridamole in myasthenia gravis, some hormones can also be used to complement the treatment.